170 related articles for article (PubMed ID: 22890557)
1. Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001.
Lan R; Lin G; Yin F; Xu J; Zhang X; Wang J; Wang Y; Gong J; Ding YH; Yang Z; Lu F; Zhang H
Lab Invest; 2012 Oct; 92(10):1503-14. PubMed ID: 22890557
[TBL] [Abstract][Full Text] [Related]
2. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY
Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386
[TBL] [Abstract][Full Text] [Related]
3. The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.
Li L; Wang X; Chen J; Ding H; Zhang Y; Hu TC; Hu LH; Jiang HL; Shen X
Acta Pharmacol Sin; 2009 Oct; 30(10):1443-53. PubMed ID: 19801998
[TBL] [Abstract][Full Text] [Related]
4. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
Gerster K; Shi W; Ng B; Yue S; Ito E; Waldron J; Gilbert R; Liu FF
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):253-60. PubMed ID: 20394857
[TBL] [Abstract][Full Text] [Related]
5. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
[TBL] [Abstract][Full Text] [Related]
6. Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1.
Raab M; Krämer A; Hehlgans S; Sanhaji M; Kurunci-Csacsko E; Dötsch C; Bug G; Ottmann O; Becker S; Pachl F; Kuster B; Strebhardt K
Mol Oncol; 2015 Jan; 9(1):140-54. PubMed ID: 25169932
[TBL] [Abstract][Full Text] [Related]
7. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
Pajtler KW; Sadowski N; Ackermann S; Althoff K; Schönbeck K; Batzke K; Schäfers S; Odersky A; Heukamp L; Astrahantseff K; Künkele A; Deubzer HE; Schramm A; Sprüssel A; Thor T; Lindner S; Eggert A; Fischer M; Schulte JH
Oncotarget; 2017 Jan; 8(4):6730-6741. PubMed ID: 28036269
[TBL] [Abstract][Full Text] [Related]
8. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
Shin SB; Woo SU; Yim H
J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
[TBL] [Abstract][Full Text] [Related]
9. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).
Uckun FM; Dibirdik I; Qazi S; Vassilev A; Ma H; Mao C; Benyumov A; Emami KH
Bioorg Med Chem; 2007 Jan; 15(2):800-14. PubMed ID: 17098432
[TBL] [Abstract][Full Text] [Related]
10. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
Gilmartin AG; Bleam MR; Richter MC; Erskine SG; Kruger RG; Madden L; Hassler DF; Smith GK; Gontarek RR; Courtney MP; Sutton D; Diamond MA; Jackson JR; Laquerre SG
Cancer Res; 2009 Sep; 69(17):6969-77. PubMed ID: 19690138
[TBL] [Abstract][Full Text] [Related]
11. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice.
Sahin K; Tuzcu M; Yabas M; Orhan C; Sahin N; Ozercan IH
Invest New Drugs; 2018 Jun; 36(3):388-395. PubMed ID: 29139009
[TBL] [Abstract][Full Text] [Related]
12. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.
Hikichi Y; Honda K; Hikami K; Miyashita H; Kaieda I; Murai S; Uchiyama N; Hasegawa M; Kawamoto T; Sato T; Ichikawa T; Cao S; Nie Z; Zhang L; Yang J; Kuida K; Kupperman E
Mol Cancer Ther; 2012 Mar; 11(3):700-9. PubMed ID: 22188812
[TBL] [Abstract][Full Text] [Related]
13. Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide-Hoechst Conjugate Suppresses Tumor Growth
Liu K; Fang L; Sun H; Pan Z; Zhang J; Chen J; Shao X; Wang W; Tan Y; Ding Z; Ao L; Wu C; Liu X; Li H; Wang R; Su W; Li H
Mol Cancer Ther; 2018 May; 17(5):988-1002. PubMed ID: 29483218
[TBL] [Abstract][Full Text] [Related]
14. Non-mitotic functions of polo-like kinases in cancer cells.
Raab CA; Raab M; Becker S; Strebhardt K
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targeting PLK1 by ON-01910.Na Is Effective in Local Treatment of Retinoblastoma.
Ma H; Nie C; Chen Y; Li J; Xie Y; Tang Z; Gao Y; Ai S; Mao Y; Sun Q; Lu R
Oncol Res; 2021 Sep; 28(7):745-761. PubMed ID: 33573708
[TBL] [Abstract][Full Text] [Related]
16. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
17. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.
Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK
PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
[TBL] [Abstract][Full Text] [Related]
20. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
